Effects of recombinant human brain natriuretic peptide on the efficacy and clinical prognosis in patients with acute myocardial infarction complicated with heart failure

A multi-center, prospective, randomized, controlled clinical trial: effects of recombinant human brain natriuretic peptide on the efficacy and clinical prognosis in patients with acute myocardial infarction complicated with heart failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022010

Enrollment

Unknown

Registered

2019-03-20

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction complicated with heart failure

Interventions

1:rhBNP

2:glyceryl trinitrateon

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. The first acute myocardial infarction (STEMI, NSTEMI) occurred within one month; 3. Killip grade I-III, or BNP > 100pg/ml, or NT-proBNP > 400pg/ml; 4. Subjects (or their legal representatives) have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Cardiogenic shock or systemic systolic blood pressure < 90 mmHg, lasting for more than 30 minutes; 2. Idiopathic cardiomyopathy complicated with valvular heart disease, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or dilated cardiomyopathy; 3. Taboos in the Use of Antiplatelet and Anticoagulant Drugs; 4. RhBNP or nitroglycerin intolerance; 5. Need for mechanical ventilation; 6. Severe non-cardiogenic diseases such as severe hepatorenal insufficiency (total bilirubin greater than 3 times the normal upper limit, serum creatinine greater than 265 mmol/L) or malignant tumors, with a life expectancy of less than 1 year; 7. Coronary revascularization with CABG.

Design outcomes

Primary

Measure	Time frame
major adverse cardiac events;	—

Countries

China

Contacts

Public ContactGu Xinshun

The Second Hospital of Hebei Medical University

13930139688@163.com+86 13930139688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026